Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Henagliflozin in Type 2 Diabetes
NCT02346175Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of henagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hengrui. Primary endpoints: Plasma pharmacokinetic parameters of SHR3824 at Day 13, Urine glucose concentration of SHR3824 at Day 11 and 1 more. Started Jun 2014; status: completed.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02346175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346175.